WillItSurvive
Pharma and healthcare groups · United States

Incyte Corporation

incyte.com ↗

Biopharma maker of Jakafi and Opzelura, focused on blood cancers and inflammatory skin disease.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Povorcitinib hidradenitis suppurativa NDA decision
The call

Incyte is profitable and growing today, but its main drug loses patent protection around 2028 and the replacement pipeline is still unproven.

Incyte makes and sells blood cancer and immune disease medicines, with one drug (Jakafi) bringing in about 60 percent of its $5.14 billion in yearly revenue. That drug's patent protection runs out around 2028, and competitors like GSK, Sobi, BMS, and AbbVie are already selling copycat versions or better alternatives that will eat into sales. The company's only real lifeline is whether its newer medicines in testing (povorcitinib, expanded Opzelura, and cancer drugs) can launch and grow fast enough to replace the money Jakafi will lose, and the next two years of clinical trial results and earnings reports will show if that bet has any real chance.

Why
01
AI pressure: None apparent. AI drug-discovery tools speed up rivals' pipelines industry-wide, but no AI lab or product directly threatens Incyte's sales today. Could AI do the core job? Unlikely.
02
Bigger players: GSK's Ojjaara, AbbVie's Rinvoq, Sobi's Vonjo, BMS's Inrebic. Rival JAK inhibitors compete for myelofibrosis and related patients, chipping at niche segments even as Jakafi's total sales still grew 11% in 2025. Could a giant copy it? Probably.
03
What protects it. FDA approvals, physician switching habits, and patent protection on Jakafi through roughly 2028 keep current revenue locked in.
What would change this call
Povorcitinib hidradenitis suppurativa NDA decision, expected 2026-2027. Approval or rejection shows whether Incyte can build a new revenue pillar before Jakafi's patent cliff.
2026 Phase III readouts for Opzelura in vitiligo and prurigo nodularis. Success or failure signals whether Opzelura can meaningfully offset Jakafi's coming decline.
Q2 2026 earnings call on July 28, 2026. Updated guidance will reveal early post-CEO-transition trajectory and confidence in the ex-Jakafi growth story.
Key numbers
  • FY2025 revenue $5.14B, up 21% YoY (2025-12-31)
  • Jakafi sales $3.09B, about 60% of revenue (2025-12-31)
  • Opzelura sales $678M, up 33% YoY (2025-12-31)
Named risks
  • Jakafi core patents expire around 2028, threatening 60% of 2025 revenue with no confirmed replacement yet. Severity: high
  • New CEO Bill Meury, in role only since June 2025, has an unproven strategic direction being tested through 2026. Severity: medium
  • Multiple approved rivals (Ojjaara, Vonjo, Inrebic) already erode Jakafi share in anemic and refractory myelofibrosis segments. Severity: medium
  • Povorcitinib and Opzelura Phase III readouts expected in 2026 could disappoint, leaving no offset for the patent cliff. Severity: high
  • Reduced Novartis royalty terms from the May 2025 settlement are time-limited, creating a future financial reset point. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
GSK (Ojjaara)gaining onOjjaara approved Sept 2023 targets anemic myelofibrosis patients, Jakafi's known weak spot
AbbVie (Rinvoq)losing toRinvoq posted $8.3 billion 2025 revenue, dwarfing Incyte's entire $5.14 billion company total
Sobi/CTI (Vonjo)contestingVonjo targets thrombocytopenic myelofibrosis patients after Sobi acquired CTI in 2023
Bristol Myers Squibb (Inrebic)contestingInrebic serves ruxolitinib-failure myelofibrosis patients as second-line alternative to Jakafi
Hengrui (jaktinib)gaining onChina approved Hengrui's jaktinib May 27, 2025, adding low-cost JAK competition in Asia
Questions people ask
Is Incyte profitable in 2026?
Yes. Incyte posted FY2025 total revenue of $5.14 billion, up 21% year-over-year, and guided 2026 revenue to $4.77 to $4.94 billion, per its Q4 2025 earnings materials dated February 10, 2026.
What happens to Incyte when Jakafi's patent expires?
Jakafi's core patents expire around 2028. Jakafi generated $3.09 billion in FY2025, about 60% of total revenue, so Incyte is racing to grow Opzelura, hematology/oncology drugs, and pipeline candidates like povorcitinib before that cliff hits, per a July 19, 2026 analysis.
Who is Incyte's biggest competitor in myelofibrosis?
GSK's Ojjaara (momelotinib), approved September 2023 after GSK's ~$1.9 billion Sierra Oncology acquisition, directly targets anemic myelofibrosis patients where Jakafi is weakest, per a June 30, 2026 JAK inhibitor competitive landscape report.
Could AI replace Incyte's drug pipeline?
No. Incyte holds FDA-approved, patent-protected drugs like Jakafi that AI cannot replicate. Instead Incyte is using AI as a tool, expanding a Genesis Molecular AI deal worth up to $120 million total in May 2026 and deploying Edison Scientific's Kosmos AI agent in R&D.
Who owns Incyte Corporation?
Incyte is an independent, publicly traded company on Nasdaq under ticker INCY, with a market cap of approximately $23.1 billion as of July 23, 2026. Julian Baker became Chairman in June 2025; there is no parent company or controlling owner.
Did Incyte settle its Novartis lawsuit?
Yes. Incyte and Novartis settled their long-running Jakafi royalty dispute on May 11, 2025. Incyte paid Novartis $280 million and agreed to a 50% reduction in future U.S. Jakafi royalty rates, generating a $242 million one-time Q2 2025 benefit.
Timeline
  • 2026-05-20Incyte expands Genesis Molecular AI deal, paying $80M upfront, up to $120M total, and partners with Edison Scientific's Kosmos AI
  • 2026-02-10Incyte issues 2026 guidance of $4.77-$4.94B revenue, core business ex-Jakafi guided to grow ~30%
  • 2025-06-26Bill Meury becomes President and CEO, succeeding Hervé Hoppenot after 11 years; Julian Baker becomes Chairman
  • 2025-05-11Incyte and Novartis settle Jakafi royalty dispute; Incyte pays $280M, accepts 50% future royalty cut
  • 2024-01-31Incyte acquires global rights to tafasitamab (Monjuvi) and pipeline assets from MorphoSys for ~$4.7B cash
  • 2023-09-30GSK's Ojjaara (momelotinib) approved for anemic myelofibrosis, directly challenging Jakafi's weak spot
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources